Naproxen sodium was administered to cynomolgus monkeys (Macaca fascicularis) by oral gavage at daily doses of 44, 88, or 176 mg/kg for 2 wk (2 monkeys/gender) or of 44 mg/kg for 13 wk (4 monkeys/gender). Body weight loss occurred in at least one monkey in all naproxen sodium-dosed groups in the 2-wk (up to 16% loss) and 13-wk (up to 22% loss) studies. Increases in plasma naproxen concentrations were dose proportional between 44 and 88 mg/kg but were less than dose proportional between 88 and 176 mg/kg. Up to 2-fold increases in creatinine and/or serum urea nitrogen values as well as higher renal weights occurred in monkeys receiving 176 mg/kg for 2 wk or 44 mg/kg for 13 wk. Microscopically, renal changes were observed in all naproxen sodium-dosed groups. Renal findings after 2 wk of exposure included increased interstitial ground substance, tubular dilatation, and tubulointerstitial nephritis; in the 13-wk study, cortical tubular atrophy and interstitial fibrosis were also observed. These studies identify the kidney as the target organ of naproxen sodium in cynomolgus monkeys.
Aabakken L., Dybdahl JH, Eisaunet W., Haaland A., Larsen S., and Osnes M. (1989). Optimal assessment of gastrointestinal side effects induced by non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol.24: 1007-1013.
2.
Adams DH, Howie AJ, Michael J., McConkey B., Bacon PA, and Adu D. (1986). Non-steroidal anti-inflammatory drugs and renal failure. Lancet1: 57-60.
3.
Bach PH, Grasso P., Molland EA, and Bridges JW (1983). Changes in medullary glycosaminoglycan histochemistry and microvascular filling during the development of 2-bromoethanamine hydrobromide-induced renal papillary necrosis. Toxicol. Appl. Pharmacol.69: 333-344.
4.
Bach PH and Thanh Ntk (1998). Renal papillary necrosis—40 years on. Toxicol. Pathol.26: 73-91.
5.
Bender WL, Whelton A., Beschorner WE, Darwish MO, Hall-Craggs M., and Solez K. (1984). Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am. J. Med.76: 1006-1012.
6.
Black HE (1986). Renal toxicity of non-steroidal anti-inflammatory drugs. Toxicol. Pathol.14: 83-90.
7.
Blackshear JL , Napier JS, Davidman M., and Stillman MT (1985). Renal complications of nonsteroidal antiinflammatory drugs: Identification and monitoring of those at risk. Semin. Arthritis Rheum.14: 163-175.
8.
Burry A. (1978). Pathology of analgesic nephropathy: Australian experience. Kidney Int.13: 34-40.
9.
Burry AF (1967). The evolution of analgesic nephropathy. Nephron5: 185-201.
10.
Cheville NF (1994). Ultrastructural Pathology. An Introduction to Interpretation, 1st ed. Iowa State University Press, Ames.
11.
Cinotti GA (1984). Clinical assessment of the renal toxicity of antirheumatic drugs. Arch. Toxicol. Suppl.7: 338-349.
12.
Clausen E. and Jensen K. (1968). Renal biopsies from patients with a high analgesic intake. Acta Pathol. Microbiol. Scand.72: 219-232.
13.
Clive DM and Stoff JS (1984). Renal syndromes associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med.310: 563-572.
14.
Cronin RE and Henrich WL (1996). Toxic nephropathy. In: Brenner & Rector's The Kidney, 5th ed., BM Brenner (ed). W. B. Saunders, Philadelphia, pp. 1680-1711.
15.
Dahl H. (1986). Naproxen (Naprosyn®). Pharmacokinetics: Therapeutical relevance and tolerance profile. Cephalalgia Suppl. 4: 69-75.
16.
Davies DJ (1968). Changes in the renal cortex following experimental medullary necrosis. Arch. Pathol.86: 377-382.
17.
De Broe ME and Elseviers MM (1998). Analgesic nephropathy. N. Engl. J. Med.338: 446-452.
18.
DeArmond B, Francisco CA, Lin J-S., Huang F-Y., Halladay S., Bartizek RD, and Skare KL (1995). Safety profile of over-the-counter naproxen sodium. Clin. Ther.17: 587-601.
19.
Devane JG, Butler J., and Mulligan S. (1996). IPDAS: A novel technology brings new benefits when applied to naproxen sodium. Am. J. Orthop.25: 7-13.
20.
Elliott GA, Purmalis A., VanderMeer DA, and Denlinger RH (1988). The propionic acids. Gastrointestinal toxicity in various species. Toxicol. Pathol.16: 245-250.
21.
Emerson JL (1976). Chronic oral toxicity of a nonsteroidal antiinflammatory agent in rhesus monkeys. Toxicol. Appl. Pharmacol.37: 184 (abstract).
22.
Erslev AJ and Besarab A. (1997). Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int.51: 622-630.
23.
Finkelstein A., Fraley DS, Stachura I., Feldman HA, Gandy DR, and Bourke E. (1982). Fenoprofen nephropathy: Lipoid nephrosis and interstitial nephritis. Am. J. Med.72: 81-87.
24.
Gault MH, Blennerhassett J., and Muehrcke RC (1971). Analgesic nephropathy: A clinicopathologic study using electron microscopy. Am. J. Med.51: 740-756.
25.
Giercksky K-E. , Huseby G., and Rugstad H-E. (1989). Epidemiology of NSAID-related gastrointestinal side effects. Scand. J. Gastroenterol. Suppl.163: 3-8.
26.
Gloor FJ (1978). Changing concepts in pathogenesis and morphology of analgesic nephropathy as seen in Europe. Kidney Int.13: 27-33.
27.
Gregg NJ, Elseviers MM, De Broe ME, and Bach PH (1989). Epidemiology and mechanistic basis of analgesic-associated nephropathy. Toxicol. Lett.46: 141-151.
28.
Hallesy DW, Shott LD, and Hill R. (1973). Comparative toxicology of naproxen. Scand. J. Rheumatol. Suppl.2: 20-28.
29.
Hallgren R. , Gerdin B., and Tufveson G. (1990). Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. Relationship to the transplantation edema. J. Exp. Med.171: 2063-2076.
30.
Insel PA (1996). Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: The Pharmacologic Basis of Therapeutics, 9th ed., JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, and AG Gilman (eds). McGraw-Hill, New York, pp. 617-657.
31.
Kaissling B. , Hegyi I., Loffing J., and Le Hir M. (1996). Morphology of interstitial cells in the healthy kidney. Anat. Embryol.193: 303-318.
32.
Krantz SB (1994). Pathogenesis and treatment of the anemia of chronic disease. Am. J. Med. Sci.307: 353-359.
33.
Lucke VM, Messervy M., Lucke JN, and Hunt AC (1968). Effects on the kidney of removal of the renal papilla. Arch. Pathol.86: 390-394.
34.
Maniglia R. , Schwartz AB, and Moriber-Katz S. (1988). Non-steroidal anti-inflammatory nephrotoxicity. Ann. Clin. Lab. Sci.18: 240-252.
35.
McAlindon ME , Cook GA, Elliott SL, Hawkey CJ, and Yeomans ND (1995). Gastric microbleeding following single and repeated dosing with naproxen. Aliment. Pharmacol. Ther.9: 655-659.
36.
Medical Economics Company, Inc. (1998). Physician's Desk Reference, 52nd ed. Medical Economics Company, Inc., Montvale, New Jersey.
37.
Molland EA (1978). Experimental renal papillary necrosis. Kidney Int.13: 5-14.
38.
Moyer S. (1986). Pharmacokinetics of naproxen sodium. Cephalalgia6: 77-80.
39.
Murray MD and Brater DC (1993). Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol.32: 435-465.
40.
Pitcock JA, Lyons H., Brown PS, Rightsel WA, and Muirhead EE (1988). Glycosaminoglycans of the rat renomedullary interstitium: Ultrastructural and biochemical observations. Exp. Mol. Pathol.49: 373-387.
41.
Pitcock JA, Rightsel WA, Brown P., Brooks B., and Muirhead EE (1976). Functional-morphological correlates of renomedullary interstitial cells. Clin. Sci. Mol. Med. Suppl. 51: 291s-293s.
42.
Reeves WB, Foley RJ, and Weinman EJ (1985). Nephrotoxicity from nonsteroidal anti-inflammatory drugs. South. Med. J.78: 318-322.
43.
Roskiewicz A., Roskiewicz J., and Zawistowski S. (1982). The effect of indomethacin on the ultrastructure of renomedullary interstitial cells of the rat. Gegenbaurs Morphol. Jahrb.128: 702-711.
44.
Runkel R., Chaplin M., Boost G., Serge E., and Forchielli E. (1972). Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J. Pharm. Sci.61: 703-708.
45.
Runkel R., Forchielli E., Sevelius H., Chaplin M., and Segre E. (1974). Nonlinear plasma level response to high doses of naproxen. Clin. Pharmacol. Ther.15: 261-266.
46.
Serge EJ (1980). Naproxen sodium (Anaprox). Pharmacology, pharmacokinetics. and drug interactions. J. Reprod. Med.25: 222-225.
47.
Serge EJ (1983). Naproxen. In: Anti-Rheumatic Drugs , EC Huskisson (ed). Praeger Publishers, New York, pp. 401-419.
48.
Sevelius H. , Runkel R., Serge E., and Bloomfield SS (1980). Bioavailability of naproxen sodium and its relationship to clinical analgesic effects. Br. J. Clin. Pharmacol.10: 259-263.
49.
Skelton-Stroud PN and Glaister JR (1987). Naturally occurring renal disease in non-human primates. In: Nephrotoxicity in the Experimental and Clinical Situation, PH Bach and EA Lock (eds). Martinus Nijhoff Publishers , Dordrecht, The Netherlands , pp. 189-210.
50.
Stachura I., Jayakumar S., and Bourke E. (1983). T and B lymphocyte subsets in fenoprofen nephropathy . Am. J. Med.75: 9-16.
51.
Thompson GF and Collins JM (1973). Urinary metabolic profiles for choosing test animals for chronic studies: Application to naproxen. J. Pharm. Sci.62: 937-941.
52.
Todd PA and Clissold SP (1990). Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs40: 91-137.
53.
Wallis PJ, Lodwick R., Sinha SK, and Constable TJ (1989). Effect of naproxen on renal haemodynamics in elderly patients with arthritis. Age Ageing18: 26-30.
54.
Whelton A., Watson AJ, and Rock RC (1996). Nitrogen metabolites and renal function. In: Tietz Fundamentals of Clinical Chemistry, 4th ed., CA Burtis and ER Ashwood (eds). W. B. Saunders Company, Philadelphia, pp. 569-591.
